Author: Ascletis Pharma Inc.

Posted Date:

June 7, 2026

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

Ascletis Pharma Inc.

June 7, 2026
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)

Ascletis Pharma Inc.

May 5, 2026
Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions

Ascletis Pharma Inc.

April 29, 2026
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

Ascletis Pharma Inc.

April 26, 2026
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

Ascletis Pharma Inc.

April 7, 2026
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models

Ascletis Pharma Inc.

March 17, 2026
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma Inc.

March 10, 2026
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

Ascletis Pharma Inc.

February 12, 2026
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Ascletis Pharma Inc.

January 29, 2026
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

Ascletis Pharma Inc.

January 28, 2026